3-rx.comCustomer Support
3-rx.com
   
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics



\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>


Join our Mailing List





Syndicate

You are here : 3-RX.com > Home > Cancer - Diabetes -

Why Does Diabetes Raise Cancer Risk?

Cancer • • DiabetesJun 17, 10

People with diabetes are at increased risk of certain cancers—but why?

Could it be that some diabetes treatments trigger or promote cancer? Or do the underlying causes of diabetes also underlie cancer?

These are the questions put before an expert panel from the American Diabetes Association and the American Cancer Society (ACS).

Their conclusion: We aren’t sure.

Even so, lifestyle changes that prevent or reverse diabetes will certainly cut cancer risk, says panel member Susan M. Gapstur, PhD, ACS vice president of epidemiology.

“The full biologic link between diabetes and cancer has not been completely defined,” Gapstur tells WebMD. “But first of all we should prevent diabetes. Then we can prevent some cancers. And for those who do have diabetes, it should be controlled as much as possible through a healthy lifestyle.”

Diabetes doubles the risk of liver, pancreas, and endometrial cancer. It increases the risk of colorectal, breast, and bladder cancer by 20% to 50%. But it cuts men’s risk of prostate cancer.

People with diabetes tend to have some known risk factors for cancer: older age, obesity, poor diet, and physical inactivity. And problems common in diabetes—too-high insulin levels, too-high blood sugar levels, and inflammation—increase cancer risk.

“No matter what science ultimately reveals ... we already know what we need to do to lower risk for both cancer and diabetes,” Alice Bender, RD, of the American Institute for Cancer Research, says in a news release. “Eat a healthy, varied, predominantly plant-based diet, be physically active every day, and maintain a healthy body weight.”
Do Diabetes Treatments Raise Cancer Risk?

There is evidence, but not definitive proof, that diabetes treatments affect cancer risk.

Metformin, the most commonly used diabetes drug, seems to lower cancer risk. But there’s also evidence from some studies—contradicted by others—that insulin, particularly long-acting insulin glargine (Lantus), may increase cancer risk.

Moreover, there are at least theoretical concerns that other relatively new diabetes drugs may affect cancer risk. Unfortunately, the panel found too little data to form an opinion on this question.

Because there is no definitive link between diabetes treatment and cancer, the panel strongly advises people with diabetes—except those at extremely high risk of cancer—not to make treatment decisions based on fear of cancer.

“Clearly those being treated for diabetes need to be talking with their doctors about the importance of regular cancer screenings as recommended by the American Cancer Society,” Gapstur says.

The consensus panel’s report appears in the July/August issue of the ACS journal CA: A Cancer Journal for Clinicians.

—-
By Daniel J. DeNoon
WebMD Health News



Print Version
Tell-a-Friend
comments powered by Disqus

RELATED ARTICLES:
  New biomarkers may influence drug design and alternative treatments of cancer, study shows
  Metabolic profiles distinguish early stage ovarian cancer with unprecedented accuracy
  Moffitt researchers develop first genetic test to predict tumor sensitivity to radiation therapy
  Implantable ‘artificial pancreas’ could help diabetes patients control their blood sugar
  New drug for neuroblastoma shows promise in phase I study
  Experimental treatment sends deadly leukemia into remission
  Study could reduce unnecessary cancer screening
  UA researchers discover component of cinnamon prevents colorectal cancer in mice
  Profiling approach to enable right lung cancer treatment match
  Fat grafting technique improves results of breast augmentation
  Germline TP53 mutations in patients with early-onset colorectal cancer
  Clinical trial suggests combination therapy is best for low-grade brain tumors

 












Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site